| Budget Amount *help |
¥5,070,000 (Direct Cost: ¥3,900,000、Indirect Cost: ¥1,170,000)
Fiscal Year 2013: ¥650,000 (Direct Cost: ¥500,000、Indirect Cost: ¥150,000)
Fiscal Year 2012: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2011: ¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
|
|---|
| Research Abstract |
The expression of amino acid transporter, LAT1/CD98 was examined in various breast cancer, because the importance of clarify the carcinogenesis and progression of the triple negative breast cancer (TNBC) is increasing. The positive ratio of LAT1 expression in luminal A cases was 7.9%, 30.0% in luminal B cases, 71.4% in HER2 cases and 64.0% in TN cases. HER2 and TN subtypes expressed LAT1 and CD98 at higher levels than luminal A and B subtypes. LAT1 and CD98 expression correlated with tumor size, nuclear grade and Ki67 labeling index. LAT1 and CD98 expression was negatively associated with ER and PgR. Multivariate analysis confirmed that CD98+ or LAT1+/CD98+ expression were risk factors for relapse in TNBC. LAT1 expression is correlated with stem cell marker, CD44 and CD24 by immunohistochemical examination, using tissue microarray. Thus, in our study we clarify the importance of LAT1 and CD98 in carcinogenesis and progression of TNBC and it might be related with stem cell.
|
